- Home
- ARVN
ARVN
Arvinas Inc.
as 07-26-2024 4:00pm EST
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 1.7B | IPO Year: | 2018 |
| Target Price: | $62.94 | AVG Volume (30 days): | 928.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.57 - $53.08 | Next Earning Date: | 08-06-2024 |
| Revenue: | $71,300,000 | Revenue Growth: | -48.07% |
| Revenue Growth (this year): | 107.46% | Revenue Growth (next year): | 30.22% |
Stock Insider Trading Activity of Arvinas Inc. (ARVN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cassidy Sean A | ARVN | Chief Financial Officer | Feb 23 '24 | Sell | $47.05 | 1,702 | $80,079.10 | 181,916 | SEC Form 4 |
| Houston John G | ARVN | President and CEO | Feb 23 '24 | Sell | $47.05 | 5,196 | $244,471.80 | 1,036,681 | SEC Form 4 |
| Taylor Ian | ARVN | Chief Scientific Officer | Feb 23 '24 | Sell | $47.05 | 1,701 | $80,032.05 | 147,522 | SEC Form 4 |
| Peck Ronald | ARVN | Chief Medical Officer | Feb 23 '24 | Sell | $47.05 | 1,699 | $79,937.95 | 67,516 | SEC Form 4 |
Latest Arvinas Inc. News
ARVN Breaking Stock News: Dive into ARVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
Investor's Business Daily
9 days ago
Biotech Arvinas Stock Earns 82 RS Rating
Zacks
9 days ago
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?
GlobeNewswire
12 days ago
Milestone Pharmaceuticals Refreshes Board of Directors
Insider Monkey
a month ago
Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating?
MT Newswires
a month ago
Arvinas Names Andrew Saik as Chief Financial Officer; Shares Rise After Hours
GlobeNewswire
a month ago
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
Zacks
a month ago
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
Compare ARVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARVN Arvinas Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.